Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.63 |
| ▸ | MAP2K4 | P45985 | 6/20 | 0.63 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.63 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.63 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866791 | 0.86 | MAP2K4 (0.69) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL2858476 | 0.84 | MAP2K4 (0.68) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL2868589 | 0.83 | MAP2K4 (0.69) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK8 | |
| Ethylene SCHEMBL27536148 | 0.82 | MAP2K4 (0.65) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL2868570 | 0.81 | MAP2K4 (0.59) | MAPK1MAP2K4MAPKAPK3MAPK6CSNK2A2 | |
| SCHEMBL2860093 | 0.81 | MAP2K4 (0.71) | MAPK1MAP2K4MAPKAPK3MAPK6 | |
| SCHEMBL2570707 | 0.80 | MAPK1 (0.57) | MAPK1MAP2K4MAPKAPK3MAPK6CSNK2A2 | |
| SCHEMBL2561009 | 0.80 | TTK (0.72) | MAPK8 | |
| SCHEMBL2863052 | 0.80 | MAP2K4 (0.62) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL5372788 | 0.79 | AURKA (0.68) | MAPK1MAP2K4MAPKAPK3MAPK6JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAP2K4 61/4885MAPKAPK3 7/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAPK1 1/4885MAP2K4 53/4885MAPKAPK3 12/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAP2K4 61/4885MAPKAPK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.